The climb of a healthcare manager professional : John Adlesich

The rise of a health industry executive professional : John Adlesich about healthcare industry trends in 2021: New supply chain models for new care settings. Health care futurists believe that by 2040, most care will be delivered at home, in outpatient settings or virtually. Adapting to this new way of care — in terms of supplies and delivery methods — will require relationships with different types of vendors, such as retailers, contract employees and technology providers. This is an exciting but huge challenge: how to reimagine supply chains to deliver non-hospital-based care in a safe, cost-effective and high-quality way at scale. Smarter, faster, predictive information. Expect to see more automation software and artificial intelligence (AI) in health care supply chains. In addition to freeing personnel from repetitive tasks, these technologies can assist decision-makers in identifying trends and providing resources to workers. For example, predictive analytics focused on population health within an organization or system could alert managers to trending disease states and their associated supply needs. Supply chain managers could use AI tools to master the new transportation logistics of getting supplies to widely dispersed home care settings and so on.

John Adlesich on behavior therapy in 2021: What Is Behavior Therapy? The basic premise of behavioral therapy stems from the Skinnerian theory of operant conditioning, which asserts that behavior is learned, and thus, can be unlearned or modified to comply with socially accepted norms. By evaluating and analyzing behaviors and subsequently offering a reward, also called a consequence, for those behaviors that are socially significant and desirable, maladaptive and/or undesirable behaviors can be reshaped or eliminated. Applied Behavioral Analysis is a highly effective method for mediating behavior across a variety of domains.

John Adlesich on healthcare industry trends: Democratic control in the Senate will also impact healthcare. For example, Washington state Senator Patty Murray will chair the Senate Committee on Health, Education, Labor, and Pensions. She has advocated for a more robust federal response on COVID-19. And Senator Ron Wyden, Oregon, leads the Finance Committee and has pushed for drug pricing reform and drug price negotiation. These appointments and nominations point to a strong emphasis on COVID-19 recovery and vaccine distribution and coordination. For example, Fauci remains as the Director of the National Institute of Allergies and Infectious Diseases, and there’s now a COVID-19 data director (Shahpar), indicating this administration will emphasize data and reporting. Also evident in these appointments is a Biden administration focus on health equity and healthcare disparities—particularly with Nunez-Smith as the first Equity Task Force Chair for COVID-19. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.

John Adlesich believes that 2021 is a crossroads year for the healthcare industry. While a balanced approach is important, there is no question that US-based sources for many products are lacking to non-existent. To remedy this imbalance, we may see tax incentives and low-cost loans that would enable American manufacturers to invest in new automation technologies, to help level the playing field with overseas companies that have access to cheap labor and fewer regulatory barriers. There may also be new requirements that government purchasers such as the Veteran’s Administration and Department of Defense purchase at least a portion of the medical products they use from domestic suppliers. More, too, should be done to incent our health care providers to purchase domestically. Such moves would go a long way to creating the demand necessary for added domestic investments. When added incentives are required, the private sector will continue to step in to reward manufacturers that place a premium on geographic diversity for their supply chains. For instance, after learning that 90 percent of all face masks were produced in China, leaving the US highly susceptible to shortages, Premier and 16 leading health systems pooled resources to take a minority stake in Prestige Ameritech, one of the nation’s only domestic producers of face masks and other personal protective equipment. In exchange for the cash infusion and long-term purchasing commitments, the company is now making 3.5 million masks per month that it ordinarily would have had little incentive to make. In November, we followed that initiative with a partnership with 34 members to invest in DeRoyal Industries for the domestic production of isolation gowns that have increasingly been difficult to find.